Kurs & Likviditet
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
TSE treatment was performed on eight advanced stage cancer patients who did not respond to conventional treatments. The evaluation showed the desirable goal of tumour shrinkage.
As earlier reported the trials are performed at the large Indian governmentally run hospital chain AIIMS - All India Institute of Medical Sciences. The trial program is part of the India-Sweden Healthcare Innovation Centre, which in turn is a part of a Swedish Indian government healthcare collaboration.
ChemoTech signed an agreement with AIIMS Jodhpur and India-Sweden Healthcare Innovation Centre on 11 November 2021 to set up a Centre of Excellence to bring forward and conduct clinical studies together with the aim of creating clinical data and evidence for the effect of the TSE treatment on various cancers.
"As a part of pre-study evaluation, we used the TSE technology for treating eight advanced stage cancer patients with different indications who no longer responded to conventional therapies. With TSE, the response obtained was good in all patients and we observed downsizing and local control of the tumour. The treatment was well tolerated by the patients and post procedural management was easy. We can duplicate these results and most likely use this as a weapon to fight against cancer in upcoming studies." - says Dr Jeewan Ram Vishnoi, Associate Professor, Department of Surgical Oncology, All India Institute of Medical Sciences, Jodhpur, India.
"Even though we are very confident in our TSE technology, it is incredibly joyful and satisfactory to hear of the patients' improvements, how our technology and the vision of the AIIMS Jodhpur clinical team has come together to achieve these early results." - says Mohan Frick, CEO of Scandinavian ChemoTech